ISPO

predictive markers

"HER2"/neu as prototypical target for the development of novel cancer drugs

A Ullrich PhD

K-ras mutation in histologically-normal tissue adjacent to lung carcinoma

P Keohavong PhD , H Mady MD , W Gao MD , M Melhem MD

Molecular markers of metastases and progression

PS Steeg , MT Hartsough , T Ouatas , SE Clare , MG Mair

Predictive assessment of multidrug resistance in hematology

P Sonneveld MD

Cyclin-dependent kinase inhibitors

D Fabbro PhD, B Chaudhuri PhD, YN Chen PhD, T Ramsey PhD, J Li Phd, G Caravatti PhD, H Fretz PhD, T Meyer PhD, P Furet PhD, S Ruetz PhD, S Sharma PhD

DNA adducts in normal tissue adjacent cancer: prostate

T Mairinger MD, G Mikuz MD FRCPath, A Gschwendtner MD